EVERSANA

Learn more about NAVLIN by EVERSANA: https://ow.ly/KBim50SpYAh Increasingly complex global commercial launches are driving demand for accurate, actionable and easy-to-understand insights at your fingertips – insights that tell you not just what is going right or wrong with your global commercial strategy, but why – and do so early enough to improve the real value of a therapy over its lifecycle. As newly appointed Senior Vice President of Product Development for EVERSANA, Gustav Ando is responding to this unmet industry need by leading the development of world-class pricing, market access, and commercial insights from NAVLIN by EVERSANA’s market-leading data and software, using technology, data, forecasting and AI tools to drive getting pharmaceutical assets to patients around the world faster.

How can EVERSANA helps clients navigate the patient journey? Explore our Market Access resource library to learn more: https://ow.ly/GuQf50Si4iE Patient engagement is pivotal to building trust, ensuring transparency and driving better health outcomes. EVERSANA’s comprehensive patient engagement solutions, which leverage cutting-edge technology and personalized strategies, ensure patients are actively involved in their care, driving demand and access for new products and fostering long-term patient loyalty. EVERSANA’s Key Strategies for Driving Patient Engagement: 1. Leverage strategic marketing expertise. 2. Facilitate effective communication about a product’s value proposition. 3. Cultivate brand awareness. 4. Distinguish offerings within the competitive landscape. 5. Drive greater patient access through direct-to-patient care models. #PatientEngagement #HealthcareSolutions #EVERSANA

Read the article: https://ow.ly/bEqE50ShpNQ Our Value & Evidence team at EVERSANA, in collaboration with other HEOR industry experts, has critically reviewed and synthesized worldwide Indirect Treatment Comparison (#ITC) guidelines. Considering the challenges of head-to-head #clinicaltrials, ITCs provide valuable insights into clinical effectiveness. These insights help regulators and reimbursement agencies make informed decisions, improving patient access to novel treatments. Recent methodological advancements have led to global guidelines outlining jurisdiction-specific methodology and best practices. This comprehensive #literaturereview highlights key ITC techniques for objective analyses and ascertains the circumstantial suitability of ITCs as a source of comparative evidence for healthcare interventions. Krista Tantakoun, Christopher Olsen, Fatemeh Mirzayeh Fashami, @Imtiaz Samjoo and Chris Cameron

Register for the webinar: https://ow.ly/8N7L50S0LU1 Join EVERSANA’s Marty Culjat for an insightful webinar on #PDURS and the #FDA's new framework for incorporating software into drug labels! This #webinar, hosted by pharmaphorum will take a deep dive into the FDA's proposed framework that allows #pharmaceutical manufacturers to add software to drug labels, provided they can demonstrate clinical benefits. This innovative move is set to revolutionize the way we look at drug labeling and patient care. #PrescriptionDrug UseRelatedSoftware #Webinar

Discover More: https://lnkd.in/eCwwiJzS Maria Bucceri Kirsch, President, Patient Services at EVERSANA highlights the importance of leveraging technology and collaboration to enhance patient support programs for those with rare diseases in PM360 Magazine. #RareDiseases #PatientSupport #HealthcareInnovation #EVERSANA

Read the blog: https://ow.ly/YCiM50S31if EVERSANA's Value & Evidence team synthesized the effectiveness of treatments received in the real-world setting after 1L CDK4/6i therapy in patients with HR+/HER2- LABC/mBC. This comprehensive systematic literature review aimed to shed light on the real-world effectiveness of treatments administered after 1L CDK4/6.. Explore their findings and understand the complexities of post-CDK4/6i therapies. #BreastCancer #Oncology Sarah Kane, Belal Howidi, Bao-Ngoc Nguyen, Joanna Bielecki and Imtiaz A. Samjoo

Discover Cannes Lions 2024 Pharma insights from Susan Perlbachs, a member of the Pharma Jury, in Med Ad News! Read More: https://lnkd.in/gy4pZgHW #CannesLions #PharmaInnovation

Congratulations to Ramaa Nathan, VP, Data Science and Real World Evidence, and Abid Rahman, SVP, Innovation, for being selected as PM360 Magazine's ELITE winners! They recently celebrated in NYC and were recognized as some of the best in the industry. #PM360ELITE

Read Article: https://ow.ly/v2p550Sa1i7 In today’s complex healthcare environment, drug manufacturers must navigate an evolving stakeholder landscape to guarantee #patientaccess. Integrated Delivery Networks (IDNs) have become key players, and understanding their objectives is crucial for launch success. Our latest article explores how #FieldDeployment teams can develop a comprehensive strategy that aligns with all stakeholders – patients, providers, payers and healthcare systems – to ensure effective product utilization.

Register for webinar: https://ow.ly/4YjF50Sif8M With India experiencing transformational growth and reduced regulatory and administrative hurdles, life sciences companies worldwide are increasingly considering India a key market for clinical and commercial opportunities. Additionally, advancements in the development and manufacturing of biopharmaceuticals and biosimilars, alongside investments in digital transformation and enhanced technology applications in the supply chain, have positioned India as a global hub for pharmaceutical and life sciences innovation. Join our webinar on July 3, 2024, at 12 pm JST to hear from our experts about how India can contribute to your company’s growth. Learn about: ✔ What are the growth drivers for India’s pharma and medical device industry ✔ Understand the changes in regulatory and administrative hurdles and attitudes ✔ Discuss how the industry is responding and what are the different scenarios that are likely to emerge ✔ Advice on how new entrants should think about their business models and key success factors. The presentation will be in English with live translation in Japanese. ~~~ 国内ヘルスケア企業の皆様へ　弊社ウェビナーのお知らせ インドのライフサイエンス市場は、急成長を目指す国内ライフサイエンス企業にとって大きなチャンスとなるとお考えでしょうか？ インドの過去の成長及び昨今実施された規制緩和や行政のハードルが下がったことで、世界のライフサイエンス企業はインドライフサイエンス市場を、臨床・ビジネスの観点から重要な市場と考えるようになってきています。特に、バイオ医薬品やバイオシミラーの開発・製造、デジタルトランスフォーメーションへの投資、サプライチェーンにおける技術応用の強化により、インドはグローバルライフサイエンス・イノベーションのハブとして注目を集めています。 本ウェビナーでは、以下について弊社専門家が詳しく解説します： • インドの製薬・医療機器産業の成長ドライバー • 規制・行政上のハードルや姿勢の変化 • 業界の対応と考えられるシナリオ • 新規参入企業がビジネスモデルや主要成功要因について考慮すべき点 日時：2024年7月3日午後12時（日本時間） 言語：英語（日本語通訳付き） 皆様のご参加を心よりお待ちしております。